Rockwell Medical, Inc. (RMTI) 10-Year Financial Performance & Capital Metrics

RMTI • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCardiovascular & Metabolic

AboutRockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.Show more

Revenue $101M +21.4%
EBITDA $3M +153.3%
Net Income -$480K +94.3%
EPS (Diluted) -0.03 +93.0%
Gross Margin 17.23% +65.5%
EBITDA Margin 2.75% +144.0%
Operating Margin 0.6% +107.5%
Net Margin -0.47% +95.3%
ROE -1.78% +96.3%
ROIC 1.62% +107.5%
Debt/Equity 0.42 -34.2%
Interest Coverage 0.48 +116.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓Strong 5Y sales CAGR of 10.6%
✓Trading at only 0.9x book value
✓Efficient asset utilization: 1.7x turnover

✗Weaknesses

✗Shares diluted 33.2% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.48%

5Y10.61%

3Y17.9%

TTM-23.6%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-346.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM-211.82%

ROCE

10Y Avg-45.8%

5Y Avg-40.55%

3Y Avg-26.17%

Latest1.51%

Peer Comparison

Cardiovascular & Metabolic

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRDLCardiol Therapeutics Inc.	96.3M	0.96	-1.89			-337.72%		0.01
TLPHTalphera, Inc.	46.14M	0.99	-1.98	-100%	-442.43%	-64.6%		0.82
ESPREsperion Therapeutics, Inc.	742.03M	3.13	-11.18	185.66%	-34.84%
RMTIRockwell Medical, Inc.	37.44M	0.95	-37.70	21.38%	-7.3%	-14.9%	8.52%	0.42

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	55.35M	53.28M	57.3M	63.39M	61.3M	62.2M	61.93M	72.81M	83.61M	101.49M
Revenue Growth %	0.02%	-0.04%	0.08%	0.11%	-0.03%	0.01%	-0%	0.18%	0.15%	0.21%
Cost of Goods Sold+	46.41M	46.53M	53.6M	64.97M	58.46M	59.47M	64.35M	68.73M	74.91M	84M
COGS % of Revenue	0.84%	0.87%	0.94%	1.02%	0.95%	0.96%	1.04%	0.94%	0.9%	0.83%
Gross Profit+	8.94M	6.75M	3.7M	-1.58M	2.84M	2.73M	-2.42M	4.08M	8.7M	17.48M
Gross Margin %	0.16%	0.13%	0.06%	-0.02%	0.05%	0.04%	-0.04%	0.06%	0.1%	0.17%
Gross Profit Growth %	0.05%	-0.24%	-0.45%	-1.43%	2.79%	-0.04%	-1.89%	2.68%	1.13%	1.01%
Operating Expenses+	24.04M	26.96M	29.62M	29.82M	36.93M	31.14M	27.92M	20.86M	15.37M	16.88M
OpEx % of Revenue	0.43%	0.51%	0.52%	0.47%	0.6%	0.5%	0.45%	0.29%	0.18%	0.17%
Selling, General & Admin	19.08M	21.12M	23.3M	23.08M	30.05M	24.05M	21.08M	17.74M	14.27M	16.86M
SG&A % of Revenue	0.34%	0.4%	0.41%	0.36%	0.49%	0.39%	0.34%	0.24%	0.17%	0.17%
Research & Development	4.96M	5.84M	6.32M	6.74M	6.89M	7.09M	6.83M	3.12M	1.11M	19K
R&D % of Revenue	0.09%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.04%	0.01%	0%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-15.1M	-20.21M	-25.92M	-32.44M	-34.1M	-28.42M	-30.34M	-16.78M	-6.67M	608K
Operating Margin %	-0.27%	-0.38%	-0.45%	-0.51%	-0.56%	-0.46%	-0.49%	-0.23%	-0.08%	0.01%
Operating Income Growth %	0.14%	-0.34%	-0.28%	-0.25%	-0.05%	0.17%	-0.07%	0.45%	0.6%	1.09%
EBITDA+	-14.28M	-19.45M	-25.41M	-31.79M	-31.44M	-26.13M	-27.82M	-16.2M	-5.23M	2.79M
EBITDA Margin %	-0.26%	-0.36%	-0.44%	-0.5%	-0.51%	-0.42%	-0.45%	-0.22%	-0.06%	0.03%
EBITDA Growth %	0.14%	-0.36%	-0.31%	-0.25%	0.01%	0.17%	-0.06%	0.42%	0.68%	1.53%
D&A (Non-Cash Add-back)	822.29K	762.37K	514.36K	650.14K	2.65M	2.29M	2.52M	576K	1.44M	2.18M
EBIT	-14.42M	-19.4M	-25.92M	-31.41M	-34.1M	-29.01M	-30.31M	-16.74M	-6.14M	774K
Net Interest Income+	681.88K	810.34K	790.23K	535.64K	367K	-1.64M	-2.34M	-1.9M	-2.09M	-1.16M
Interest Income	681.88K	810.34K	790.23K	535.33K	367.08K	238K	22K	33K	211K	92K
Interest Expense	0	0	0	0	0	1.88M	2.36M	1.94M	2.3M	1.25M
Other Income/Expense	681.88K	810.34K	1.63K	-716.7K	-3.08M	-2.47M	-2.34M	-1.9M	-1.77M	-1.09M
Pretax Income+	-14.42M	-19.4M	-25.92M	-32.13M	-37.18M	-30.89M	-32.67M	-18.68M	-8.44M	-480K
Pretax Margin %	-0.26%	-0.36%	-0.45%	-0.51%	-0.61%	-0.5%	-0.53%	-0.26%	-0.1%	-0%
Income Tax+	0	404.53K	-1.63K	313.3K	-3.05M	0	0	0	0	0
Effective Tax Rate %	1%	1.02%	1%	1%	0.92%	1%	1%	1%	1%	1%
Net Income+	-14.42M	-19.8M	-25.92M	-32.13M	-34.13M	-30.89M	-32.67M	-18.68M	-8.44M	-480K
Net Margin %	-0.26%	-0.37%	-0.45%	-0.51%	-0.56%	-0.5%	-0.53%	-0.26%	-0.1%	-0%
Net Income Growth %	0.32%	-0.37%	-0.31%	-0.24%	-0.06%	0.09%	-0.06%	0.43%	0.55%	0.94%
Net Income (Continuing)	-14.42M	-19.8M	-25.92M	-32.13M	-34.13M	-30.89M	-32.67M	-18.68M	-8.44M	-480K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.19	-4.29	-5.61	-6.69	-5.61	-4.49	-3.83	-1.89	-0.36	-0.03
EPS Growth %	0.44%	-0.34%	-0.31%	-0.19%	0.16%	0.2%	0.15%	0.51%	0.81%	0.93%
EPS (Basic)	-3.19	-4.30	-5.61	-6.69	-5.61	-4.49	-3.83	-1.89	-0.36	-0.03
Diluted Shares Outstanding	4.52M	4.62M	4.62M	4.8M	5.54M	6.87M	8.53M	9.87M	23.32M	31.06M
Basic Shares Outstanding	4.52M	4.61M	4.62M	4.8M	5.54M	6.87M	8.53M	9.87M	23.32M	31.06M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	84.63M	78.51M	48.83M	46.83M	36.87M	69.47M	35.29M	35.31M	28.77M	37.03M
Cash & Short-Term Investments	70.68M	57.94M	33.06M	33.53M	26.05M	58.68M	22.44M	21.49M	10.94M	21.6M
Cash Only	31.2M	17.18M	8.41M	22.71M	11.79M	48.68M	13.28M	10.1M	8.98M	15.66M
Short-Term Investments	39.48M	40.76M	24.65M	10.82M	14.25M	10M	9.16M	11.39M	1.95M	5.94M
Accounts Receivable	5.05M	6.39M	6.36M	7.35M	4.2M	4.17M	5.91M	6.26M	10.9M	8.29M
Days Sales Outstanding	33.28	43.79	40.48	42.33	25.02	24.48	34.85	31.38	47.59	29.82
Inventory	7.87M	12.14M	7.64M	4.04M	3.65M	3.91M	4.08M	5.81M	5.87M	5.78M
Days Inventory Outstanding	61.91	95.24	52.01	22.69	22.77	24.02	23.12	30.87	28.61	25.11
Other Current Assets	1.03M	2.03M	0	0	0	0	0	1.75M	1.06M	1.36M
Total Non-Current Assets+	3.2M	4.64M	9.95M	5.73M	7.44M	8.28M	13.29M	11.32M	23.4M	22.18M
Property, Plant & Equipment	1.65M	1.39M	2.55M	2.64M	5.65M	5.55M	10.22M	8.61M	11.02M	10.34M
Fixed Asset Turnover	33.62x	38.29x	22.48x	24.03x	10.86x	11.20x	6.06x	8.46x	7.59x	9.81x
Goodwill	920.75K	920.75K	920.75K	920.75K	921K	921K	921K	921K	921K	921K
Intangible Assets	165.66K	4.38K	4.03K	0	0	0	0	0	10.76M	10.21M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	462.84K	2.33M	6.48M	2.17M	876K	1.8M	2.14M	1.8M	705K	706K
Total Assets+	87.82M	83.15M	58.78M	52.56M	44.32M	77.75M	48.57M	46.63M	52.17M	59.21M
Asset Turnover	0.63x	0.64x	0.97x	1.21x	1.38x	0.80x	1.27x	1.56x	1.60x	1.71x
Asset Growth %	-0.1%	-0.05%	-0.29%	-0.11%	-0.16%	0.75%	-0.38%	-0.04%	0.12%	0.13%
Total Current Liabilities+	8.09M	10.15M	9.14M	13.2M	12.37M	12.79M	20.97M	17.69M	16.64M	14.09M
Accounts Payable	4M	5.86M	4.22M	4.49M	3.02M	4.16M	3.74M	4.05M	4.52M	2.87M
Days Payables Outstanding	31.42	45.95	28.75	25.24	18.84	25.5	21.21	21.52	22	12.47
Short-Term Debt	0	0	0	0	763K	0	7.82M	2.13M	244K	268K
Deferred Revenue (Current)	264.88K	77.22K	205.3K	1000K	1000K	1000K	1000K	1000K	289K	143K
Other Current Liabilities	1.89M	2M	1.99M	2.38M	1.49M	3.03M	2.17M	2.87M	5.17M	5.29M
Current Ratio	10.46x	7.74x	5.34x	3.55x	2.98x	5.43x	1.68x	2.00x	1.73x	2.63x
Quick Ratio	9.49x	6.54x	4.51x	3.24x	2.69x	5.12x	1.49x	1.67x	1.38x	2.22x
Cash Conversion Cycle	63.77	93.08	63.74	39.78	28.95	22.99	36.76	40.73	54.19	42.46
Total Non-Current Liabilities+	17.41M	20.05M	16.72M	12.08M	11.62M	30.79M	25.07M	14.84M	14.24M	12.53M
Long-Term Debt	0	0	0	0	0	20.95M	13.19M	7.55M	8.29M	8.47M
Capital Lease Obligations	0	0	0	0	1.78M	1.82M	5.89M	4.67M	2.96M	2.63M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	14K	14K	2.51M	1M
Total Liabilities	25.5M	30.2M	25.87M	25.28M	24M	43.58M	46.04M	32.53M	30.88M	26.62M
Total Debt+	0	0	0	0	4.04M	23.94M	28.89M	16.36M	13.44M	13.54M
Net Debt	-31.2M	-17.18M	-8.41M	-22.71M	-7.76M	-24.75M	15.62M	6.26M	4.46M	-2.13M
Debt / Equity	-	-	-	-	0.20x	0.70x	11.40x	1.16x	0.63x	0.42x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	4.85x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-0.76x
Interest Coverage	-	-	-	-	-	-15.13x	-12.85x	-8.67x	-2.90x	0.48x
Total Equity+	62.32M	52.96M	32.91M	27.28M	20.32M	34.17M	2.54M	14.11M	21.29M	32.59M
Equity Growth %	-0.09%	-0.15%	-0.38%	-0.17%	-0.26%	0.68%	-0.93%	4.56%	0.51%	0.53%
Book Value per Share	13.79	11.47	7.12	5.68	3.67	4.97	0.30	1.43	0.91	1.05
Total Shareholders' Equity	62.32M	52.96M	32.91M	27.28M	20.32M	34.17M	2.54M	14.11M	21.29M	32.59M
Common Stock	257.77M	268.2M	273.21M	5.7K	7K	9K	1K	1K	3K	3K
Retained Earnings	-194.54M	-214.34M	-240.26M	-272.39M	-306.52M	-337.41M	-370.08M	-388.76M	-397.2M	-397.68M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-915.5K	-902.55K	-35.38K	63.15K	52K	57K	52K	163K	-1K	54K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.24M	-12.45M	-21.11M	-20.42M	-27.25M	-29.64M	-33.53M	-16.93M	-9.41M	4.2M
Operating CF Margin %	-0.29%	-0.23%	-0.37%	-0.32%	-0.44%	-0.48%	-0.54%	-0.23%	-0.11%	0.04%
Operating CF Growth %	-4.81%	0.23%	-0.7%	0.03%	-0.33%	-0.09%	-0.13%	0.5%	0.44%	1.45%
Net Income	-14.42M	-19.8M	-25.92M	-32.13M	-34.13M	-30.89M	-32.67M	-18.68M	-8.44M	-480K
Depreciation & Amortization	822.29K	762.37K	514.36K	650.14K	2.65M	2.29M	2.52M	576K	1.44M	2.18M
Stock-Based Compensation	8.89M	10.35M	7.17M	4.39M	4.95M	475K	943K	315K	932K	1.29M
Deferred Taxes	63.38K	-10.31M	0	9M	0	0	156K	0	0	0
Other Non-Cash Items	-2.91M	10.35M	802.98K	1.1M	1.24M	1.44M	369K	2.98M	3.9M	2.74M
Working Capital Changes	-8.68M	-3.79M	-3.68M	-3.43M	-1.98M	-2.96M	-4.84M	-2.13M	-7.24M	-1.53M
Change in Receivables	-574.73K	-1.16M	-962.34K	-623.95K	2.78M	32K	-1.74M	-346K	-4.64M	2.61M
Change in Inventory	-3.95M	-6.1M	343.49K	-835.64K	316.87K	-1.31M	-656K	-2.1M	1.18M	-332K
Change in Payables	-1.3M	1.86M	-1.64M	269.91K	-1.47M	1.14M	-416K	314K	463K	-1.65M
Cash from Investing+	-21.14M	-1.64M	14.5M	12.72M	-4.75M	3.21M	311K	-2.4M	-3.04M	-4.87M
Capital Expenditures	-815K	-355.26K	-1.68M	-994.26K	-1.34M	-1.05M	-522K	-281K	-284K	-1.01M
CapEx % of Revenue	0.01%	0.01%	0.03%	0.02%	0.02%	0.02%	0.01%	0%	0%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	4.8K	1K	725	250.4K	-750K	0	833K	0	0	0
Cash from Financing+	2.78M	80.16K	-2.16M	22M	21.08M	63.32M	-2.18M	16.15M	11.34M	7.35M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.91M	0	-2.29M	3.5K	-1.65M	-3.88M	-6K	-191K	-5K	-1.63M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-17.06M	-12.81M	-22.8M	-21.41M	-28.59M	-30.69M	-34.06M	-17.21M	-9.7M	3.19M
FCF Margin %	-0.31%	-0.24%	-0.4%	-0.34%	-0.47%	-0.49%	-0.55%	-0.24%	-0.12%	0.03%
FCF Growth %	-5.77%	0.25%	-0.78%	0.06%	-0.34%	-0.07%	-0.11%	0.49%	0.44%	1.33%
FCF per Share	-3.77	-2.77	-4.93	-4.46	-5.16	-4.46	-3.99	-1.74	-0.42	0.10
FCF Conversion (FCF/Net Income)	1.13x	0.63x	0.81x	0.64x	0.80x	0.96x	1.03x	0.91x	1.12x	-8.75x
Interest Paid	0	0	0	0	0	1.56M	0	1.47M	1.21M	847K
Taxes Paid	0	404.53K	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-22.01%	-34.36%	-60.37%	-106.75%	-143.4%	-113.38%	-178.04%	-224.49%	-47.68%	-1.78%
Return on Invested Capital (ROIC)	-66.58%	-45.31%	-64.5%	-167.39%	-298.65%	-193.89%	-165.02%	-65.35%	-21.7%	1.62%
Gross Margin	16.15%	12.67%	6.46%	-2.5%	4.63%	4.38%	-3.91%	5.6%	10.41%	17.23%
Net Margin	-26.05%	-37.16%	-45.24%	-50.68%	-55.67%	-49.66%	-52.76%	-25.65%	-10.09%	-0.47%
Debt / Equity	-	-	-	-	0.20x	0.70x	11.40x	1.16x	0.63x	0.42x
Interest Coverage	-	-	-	-	-	-15.13x	-12.85x	-8.67x	-2.90x	0.48x
FCF Conversion	1.13x	0.63x	0.81x	0.64x	0.80x	0.96x	1.03x	0.91x	1.12x	-8.75x
Revenue Growth	2.14%	-3.73%	7.54%	10.63%	-3.29%	1.46%	-0.43%	17.57%	14.84%	21.38%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Concentrate Products	-	-	-	-	-	81.27M	101.44M
Concentrate Products Growth	-	-	-	-	-	-	24.82%
Drug Revenue	-	-	-	-	-	2.34M	46K
Drug Revenue Growth	-	-	-	-	-	-	-98.03%
Upfront Fee	-	-	2M	1.9M	2.5M	-	-
Upfront Fee Growth	-	-	-	-5.00%	31.58%	-	-
Product	-	59M	-	-	-	-	-
Product Growth	-	-	-	-	-	-	-
License	-	2.3M	-	-	-	-	-
License Growth	-	-	-	-	-	-	-

Revenue by Geography

	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	272K	910K	835K	561K	74.34M	92.26M
UNITED STATES Growth	-	-	234.56%	-8.24%	-32.81%	13151.87%	24.10%
Non-US	-	273K	226K	241K	598K	9.27M	9.23M
Non-US Growth	-	-	-17.22%	6.64%	148.13%	1450.00%	-0.41%
U	54.38M	-	-	-	-	-	-
U Growth	-	-	-	-	-	-	-
Non Us	9M	-	-	-	-	-	-
Non Us Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Rockwell Medical, Inc. (RMTI) reported $75.6M in revenue for fiscal year 2024. This represents a 54% increase from $49.0M in 2011.

Rockwell Medical, Inc. (RMTI) grew revenue by 21.4% over the past year. This is strong growth.

Rockwell Medical, Inc. (RMTI) reported a net loss of $5.5M for fiscal year 2024.

Dividend & Returns

Rockwell Medical, Inc. (RMTI) has a return on equity (ROE) of -1.8%. Negative ROE indicates the company is unprofitable.

Rockwell Medical, Inc. (RMTI) had negative free cash flow of $2.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Rockwell Medical, Inc. (RMTI) 10-Year Financial Performance & Capital Metrics

RMTI • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCardiovascular & Metabolic

Revenue $101M +21.4%
EBITDA $3M +153.3%
Net Income -$480K +94.3%
EPS (Diluted) -0.03 +93.0%
Gross Margin 17.23% +65.5%
EBITDA Margin 2.75% +144.0%
Operating Margin 0.6% +107.5%
Net Margin -0.47% +95.3%
ROE -1.78% +96.3%
ROIC 1.62% +107.5%
Debt/Equity 0.42 -34.2%
Interest Coverage 0.48 +116.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓Strong 5Y sales CAGR of 10.6%
✓Trading at only 0.9x book value
✓Efficient asset utilization: 1.7x turnover

✗Weaknesses

✗Shares diluted 33.2% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.48%

5Y10.61%

3Y17.9%

TTM-23.6%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-346.28%

EPS CAGR

10Y-

5Y-

3Y-

TTM-211.82%

ROCE

10Y Avg-45.8%

5Y Avg-40.55%

3Y Avg-26.17%

Latest1.51%

Peer Comparison

Cardiovascular & Metabolic

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CRDLCardiol Therapeutics Inc.	96.3M	0.96	-1.89			-337.72%		0.01
TLPHTalphera, Inc.	46.14M	0.99	-1.98	-100%	-442.43%	-64.6%		0.82
ESPREsperion Therapeutics, Inc.	742.03M	3.13	-11.18	185.66%	-34.84%
RMTIRockwell Medical, Inc.	37.44M	0.95	-37.70	21.38%	-7.3%	-14.9%	8.52%	0.42

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	55.35M	53.28M	57.3M	63.39M	61.3M	62.2M	61.93M	72.81M	83.61M	101.49M
Revenue Growth %	0.02%	-0.04%	0.08%	0.11%	-0.03%	0.01%	-0%	0.18%	0.15%	0.21%
Cost of Goods Sold+	46.41M	46.53M	53.6M	64.97M	58.46M	59.47M	64.35M	68.73M	74.91M	84M
COGS % of Revenue	0.84%	0.87%	0.94%	1.02%	0.95%	0.96%	1.04%	0.94%	0.9%	0.83%
Gross Profit+	8.94M	6.75M	3.7M	-1.58M	2.84M	2.73M	-2.42M	4.08M	8.7M	17.48M
Gross Margin %	0.16%	0.13%	0.06%	-0.02%	0.05%	0.04%	-0.04%	0.06%	0.1%	0.17%
Gross Profit Growth %	0.05%	-0.24%	-0.45%	-1.43%	2.79%	-0.04%	-1.89%	2.68%	1.13%	1.01%
Operating Expenses+	24.04M	26.96M	29.62M	29.82M	36.93M	31.14M	27.92M	20.86M	15.37M	16.88M
OpEx % of Revenue	0.43%	0.51%	0.52%	0.47%	0.6%	0.5%	0.45%	0.29%	0.18%	0.17%
Selling, General & Admin	19.08M	21.12M	23.3M	23.08M	30.05M	24.05M	21.08M	17.74M	14.27M	16.86M
SG&A % of Revenue	0.34%	0.4%	0.41%	0.36%	0.49%	0.39%	0.34%	0.24%	0.17%	0.17%
Research & Development	4.96M	5.84M	6.32M	6.74M	6.89M	7.09M	6.83M	3.12M	1.11M	19K
R&D % of Revenue	0.09%	0.11%	0.11%	0.11%	0.11%	0.11%	0.11%	0.04%	0.01%	0%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-15.1M	-20.21M	-25.92M	-32.44M	-34.1M	-28.42M	-30.34M	-16.78M	-6.67M	608K
Operating Margin %	-0.27%	-0.38%	-0.45%	-0.51%	-0.56%	-0.46%	-0.49%	-0.23%	-0.08%	0.01%
Operating Income Growth %	0.14%	-0.34%	-0.28%	-0.25%	-0.05%	0.17%	-0.07%	0.45%	0.6%	1.09%
EBITDA+	-14.28M	-19.45M	-25.41M	-31.79M	-31.44M	-26.13M	-27.82M	-16.2M	-5.23M	2.79M
EBITDA Margin %	-0.26%	-0.36%	-0.44%	-0.5%	-0.51%	-0.42%	-0.45%	-0.22%	-0.06%	0.03%
EBITDA Growth %	0.14%	-0.36%	-0.31%	-0.25%	0.01%	0.17%	-0.06%	0.42%	0.68%	1.53%
D&A (Non-Cash Add-back)	822.29K	762.37K	514.36K	650.14K	2.65M	2.29M	2.52M	576K	1.44M	2.18M
EBIT	-14.42M	-19.4M	-25.92M	-31.41M	-34.1M	-29.01M	-30.31M	-16.74M	-6.14M	774K
Net Interest Income+	681.88K	810.34K	790.23K	535.64K	367K	-1.64M	-2.34M	-1.9M	-2.09M	-1.16M
Interest Income	681.88K	810.34K	790.23K	535.33K	367.08K	238K	22K	33K	211K	92K
Interest Expense	0	0	0	0	0	1.88M	2.36M	1.94M	2.3M	1.25M
Other Income/Expense	681.88K	810.34K	1.63K	-716.7K	-3.08M	-2.47M	-2.34M	-1.9M	-1.77M	-1.09M
Pretax Income+	-14.42M	-19.4M	-25.92M	-32.13M	-37.18M	-30.89M	-32.67M	-18.68M	-8.44M	-480K
Pretax Margin %	-0.26%	-0.36%	-0.45%	-0.51%	-0.61%	-0.5%	-0.53%	-0.26%	-0.1%	-0%
Income Tax+	0	404.53K	-1.63K	313.3K	-3.05M	0	0	0	0	0
Effective Tax Rate %	1%	1.02%	1%	1%	0.92%	1%	1%	1%	1%	1%
Net Income+	-14.42M	-19.8M	-25.92M	-32.13M	-34.13M	-30.89M	-32.67M	-18.68M	-8.44M	-480K
Net Margin %	-0.26%	-0.37%	-0.45%	-0.51%	-0.56%	-0.5%	-0.53%	-0.26%	-0.1%	-0%
Net Income Growth %	0.32%	-0.37%	-0.31%	-0.24%	-0.06%	0.09%	-0.06%	0.43%	0.55%	0.94%
Net Income (Continuing)	-14.42M	-19.8M	-25.92M	-32.13M	-34.13M	-30.89M	-32.67M	-18.68M	-8.44M	-480K
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.19	-4.29	-5.61	-6.69	-5.61	-4.49	-3.83	-1.89	-0.36	-0.03
EPS Growth %	0.44%	-0.34%	-0.31%	-0.19%	0.16%	0.2%	0.15%	0.51%	0.81%	0.93%
EPS (Basic)	-3.19	-4.30	-5.61	-6.69	-5.61	-4.49	-3.83	-1.89	-0.36	-0.03
Diluted Shares Outstanding	4.52M	4.62M	4.62M	4.8M	5.54M	6.87M	8.53M	9.87M	23.32M	31.06M
Basic Shares Outstanding	4.52M	4.61M	4.62M	4.8M	5.54M	6.87M	8.53M	9.87M	23.32M	31.06M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	84.63M	78.51M	48.83M	46.83M	36.87M	69.47M	35.29M	35.31M	28.77M	37.03M
Cash & Short-Term Investments	70.68M	57.94M	33.06M	33.53M	26.05M	58.68M	22.44M	21.49M	10.94M	21.6M
Cash Only	31.2M	17.18M	8.41M	22.71M	11.79M	48.68M	13.28M	10.1M	8.98M	15.66M
Short-Term Investments	39.48M	40.76M	24.65M	10.82M	14.25M	10M	9.16M	11.39M	1.95M	5.94M
Accounts Receivable	5.05M	6.39M	6.36M	7.35M	4.2M	4.17M	5.91M	6.26M	10.9M	8.29M
Days Sales Outstanding	33.28	43.79	40.48	42.33	25.02	24.48	34.85	31.38	47.59	29.82
Inventory	7.87M	12.14M	7.64M	4.04M	3.65M	3.91M	4.08M	5.81M	5.87M	5.78M
Days Inventory Outstanding	61.91	95.24	52.01	22.69	22.77	24.02	23.12	30.87	28.61	25.11
Other Current Assets	1.03M	2.03M	0	0	0	0	0	1.75M	1.06M	1.36M
Total Non-Current Assets+	3.2M	4.64M	9.95M	5.73M	7.44M	8.28M	13.29M	11.32M	23.4M	22.18M
Property, Plant & Equipment	1.65M	1.39M	2.55M	2.64M	5.65M	5.55M	10.22M	8.61M	11.02M	10.34M
Fixed Asset Turnover	33.62x	38.29x	22.48x	24.03x	10.86x	11.20x	6.06x	8.46x	7.59x	9.81x
Goodwill	920.75K	920.75K	920.75K	920.75K	921K	921K	921K	921K	921K	921K
Intangible Assets	165.66K	4.38K	4.03K	0	0	0	0	0	10.76M	10.21M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	462.84K	2.33M	6.48M	2.17M	876K	1.8M	2.14M	1.8M	705K	706K
Total Assets+	87.82M	83.15M	58.78M	52.56M	44.32M	77.75M	48.57M	46.63M	52.17M	59.21M
Asset Turnover	0.63x	0.64x	0.97x	1.21x	1.38x	0.80x	1.27x	1.56x	1.60x	1.71x
Asset Growth %	-0.1%	-0.05%	-0.29%	-0.11%	-0.16%	0.75%	-0.38%	-0.04%	0.12%	0.13%
Total Current Liabilities+	8.09M	10.15M	9.14M	13.2M	12.37M	12.79M	20.97M	17.69M	16.64M	14.09M
Accounts Payable	4M	5.86M	4.22M	4.49M	3.02M	4.16M	3.74M	4.05M	4.52M	2.87M
Days Payables Outstanding	31.42	45.95	28.75	25.24	18.84	25.5	21.21	21.52	22	12.47
Short-Term Debt	0	0	0	0	763K	0	7.82M	2.13M	244K	268K
Deferred Revenue (Current)	264.88K	77.22K	205.3K	1000K	1000K	1000K	1000K	1000K	289K	143K
Other Current Liabilities	1.89M	2M	1.99M	2.38M	1.49M	3.03M	2.17M	2.87M	5.17M	5.29M
Current Ratio	10.46x	7.74x	5.34x	3.55x	2.98x	5.43x	1.68x	2.00x	1.73x	2.63x
Quick Ratio	9.49x	6.54x	4.51x	3.24x	2.69x	5.12x	1.49x	1.67x	1.38x	2.22x
Cash Conversion Cycle	63.77	93.08	63.74	39.78	28.95	22.99	36.76	40.73	54.19	42.46
Total Non-Current Liabilities+	17.41M	20.05M	16.72M	12.08M	11.62M	30.79M	25.07M	14.84M	14.24M	12.53M
Long-Term Debt	0	0	0	0	0	20.95M	13.19M	7.55M	8.29M	8.47M
Capital Lease Obligations	0	0	0	0	1.78M	1.82M	5.89M	4.67M	2.96M	2.63M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	14K	14K	2.51M	1M
Total Liabilities	25.5M	30.2M	25.87M	25.28M	24M	43.58M	46.04M	32.53M	30.88M	26.62M
Total Debt+	0	0	0	0	4.04M	23.94M	28.89M	16.36M	13.44M	13.54M
Net Debt	-31.2M	-17.18M	-8.41M	-22.71M	-7.76M	-24.75M	15.62M	6.26M	4.46M	-2.13M
Debt / Equity	-	-	-	-	0.20x	0.70x	11.40x	1.16x	0.63x	0.42x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	4.85x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-0.76x
Interest Coverage	-	-	-	-	-	-15.13x	-12.85x	-8.67x	-2.90x	0.48x
Total Equity+	62.32M	52.96M	32.91M	27.28M	20.32M	34.17M	2.54M	14.11M	21.29M	32.59M
Equity Growth %	-0.09%	-0.15%	-0.38%	-0.17%	-0.26%	0.68%	-0.93%	4.56%	0.51%	0.53%
Book Value per Share	13.79	11.47	7.12	5.68	3.67	4.97	0.30	1.43	0.91	1.05
Total Shareholders' Equity	62.32M	52.96M	32.91M	27.28M	20.32M	34.17M	2.54M	14.11M	21.29M	32.59M
Common Stock	257.77M	268.2M	273.21M	5.7K	7K	9K	1K	1K	3K	3K
Retained Earnings	-194.54M	-214.34M	-240.26M	-272.39M	-306.52M	-337.41M	-370.08M	-388.76M	-397.2M	-397.68M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-915.5K	-902.55K	-35.38K	63.15K	52K	57K	52K	163K	-1K	54K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.24M	-12.45M	-21.11M	-20.42M	-27.25M	-29.64M	-33.53M	-16.93M	-9.41M	4.2M
Operating CF Margin %	-0.29%	-0.23%	-0.37%	-0.32%	-0.44%	-0.48%	-0.54%	-0.23%	-0.11%	0.04%
Operating CF Growth %	-4.81%	0.23%	-0.7%	0.03%	-0.33%	-0.09%	-0.13%	0.5%	0.44%	1.45%
Net Income	-14.42M	-19.8M	-25.92M	-32.13M	-34.13M	-30.89M	-32.67M	-18.68M	-8.44M	-480K
Depreciation & Amortization	822.29K	762.37K	514.36K	650.14K	2.65M	2.29M	2.52M	576K	1.44M	2.18M
Stock-Based Compensation	8.89M	10.35M	7.17M	4.39M	4.95M	475K	943K	315K	932K	1.29M
Deferred Taxes	63.38K	-10.31M	0	9M	0	0	156K	0	0	0
Other Non-Cash Items	-2.91M	10.35M	802.98K	1.1M	1.24M	1.44M	369K	2.98M	3.9M	2.74M
Working Capital Changes	-8.68M	-3.79M	-3.68M	-3.43M	-1.98M	-2.96M	-4.84M	-2.13M	-7.24M	-1.53M
Change in Receivables	-574.73K	-1.16M	-962.34K	-623.95K	2.78M	32K	-1.74M	-346K	-4.64M	2.61M
Change in Inventory	-3.95M	-6.1M	343.49K	-835.64K	316.87K	-1.31M	-656K	-2.1M	1.18M	-332K
Change in Payables	-1.3M	1.86M	-1.64M	269.91K	-1.47M	1.14M	-416K	314K	463K	-1.65M
Cash from Investing+	-21.14M	-1.64M	14.5M	12.72M	-4.75M	3.21M	311K	-2.4M	-3.04M	-4.87M
Capital Expenditures	-815K	-355.26K	-1.68M	-994.26K	-1.34M	-1.05M	-522K	-281K	-284K	-1.01M
CapEx % of Revenue	0.01%	0.01%	0.03%	0.02%	0.02%	0.02%	0.01%	0%	0%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	4.8K	1K	725	250.4K	-750K	0	833K	0	0	0
Cash from Financing+	2.78M	80.16K	-2.16M	22M	21.08M	63.32M	-2.18M	16.15M	11.34M	7.35M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.91M	0	-2.29M	3.5K	-1.65M	-3.88M	-6K	-191K	-5K	-1.63M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-17.06M	-12.81M	-22.8M	-21.41M	-28.59M	-30.69M	-34.06M	-17.21M	-9.7M	3.19M
FCF Margin %	-0.31%	-0.24%	-0.4%	-0.34%	-0.47%	-0.49%	-0.55%	-0.24%	-0.12%	0.03%
FCF Growth %	-5.77%	0.25%	-0.78%	0.06%	-0.34%	-0.07%	-0.11%	0.49%	0.44%	1.33%
FCF per Share	-3.77	-2.77	-4.93	-4.46	-5.16	-4.46	-3.99	-1.74	-0.42	0.10
FCF Conversion (FCF/Net Income)	1.13x	0.63x	0.81x	0.64x	0.80x	0.96x	1.03x	0.91x	1.12x	-8.75x
Interest Paid	0	0	0	0	0	1.56M	0	1.47M	1.21M	847K
Taxes Paid	0	404.53K	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-22.01%	-34.36%	-60.37%	-106.75%	-143.4%	-113.38%	-178.04%	-224.49%	-47.68%	-1.78%
Return on Invested Capital (ROIC)	-66.58%	-45.31%	-64.5%	-167.39%	-298.65%	-193.89%	-165.02%	-65.35%	-21.7%	1.62%
Gross Margin	16.15%	12.67%	6.46%	-2.5%	4.63%	4.38%	-3.91%	5.6%	10.41%	17.23%
Net Margin	-26.05%	-37.16%	-45.24%	-50.68%	-55.67%	-49.66%	-52.76%	-25.65%	-10.09%	-0.47%
Debt / Equity	-	-	-	-	0.20x	0.70x	11.40x	1.16x	0.63x	0.42x
Interest Coverage	-	-	-	-	-	-15.13x	-12.85x	-8.67x	-2.90x	0.48x
FCF Conversion	1.13x	0.63x	0.81x	0.64x	0.80x	0.96x	1.03x	0.91x	1.12x	-8.75x
Revenue Growth	2.14%	-3.73%	7.54%	10.63%	-3.29%	1.46%	-0.43%	17.57%	14.84%	21.38%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Concentrate Products	-	-	-	-	-	81.27M	101.44M
Concentrate Products Growth	-	-	-	-	-	-	24.82%
Drug Revenue	-	-	-	-	-	2.34M	46K
Drug Revenue Growth	-	-	-	-	-	-	-98.03%
Upfront Fee	-	-	2M	1.9M	2.5M	-	-
Upfront Fee Growth	-	-	-	-5.00%	31.58%	-	-
Product	-	59M	-	-	-	-	-
Product Growth	-	-	-	-	-	-	-
License	-	2.3M	-	-	-	-	-
License Growth	-	-	-	-	-	-	-

Revenue by Geography

	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	272K	910K	835K	561K	74.34M	92.26M
UNITED STATES Growth	-	-	234.56%	-8.24%	-32.81%	13151.87%	24.10%
Non-US	-	273K	226K	241K	598K	9.27M	9.23M
Non-US Growth	-	-	-17.22%	6.64%	148.13%	1450.00%	-0.41%
U	54.38M	-	-	-	-	-	-
U Growth	-	-	-	-	-	-	-
Non Us	9M	-	-	-	-	-	-
Non Us Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Rockwell Medical, Inc. (RMTI) reported $75.6M in revenue for fiscal year 2024. This represents a 54% increase from $49.0M in 2011.

Rockwell Medical, Inc. (RMTI) grew revenue by 21.4% over the past year. This is strong growth.

Rockwell Medical, Inc. (RMTI) reported a net loss of $5.5M for fiscal year 2024.

Dividend & Returns

Rockwell Medical, Inc. (RMTI) has a return on equity (ROE) of -1.8%. Negative ROE indicates the company is unprofitable.

Rockwell Medical, Inc. (RMTI) had negative free cash flow of $2.9M in fiscal year 2024, likely due to heavy capital investments.